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Abstract
Parkinson’s disease is a neurodegenerative movement disorder characterized by loss of midbrain
dopaminergic neurons leading to motor abnormalities and autonomic dysfunctions. Despite intensive
research, the etiology of Parkinson’s disease remains poorly understood leaving us with no effective
therapeutic options. However, the recent identification of genes linked to heritable forms of
Parkinson’s disease has revolutionized research in the field and has begun to provide new clues to
disease pathogenesis. Here we discuss these recent genetic advances and highlight their significance in
our quest to better understand common underlying disease mechanisms that will help us identify
innovative neuroprotective therapies for Parkinson’s disease.
Introduction
Parkinson’s disease is the second most common
neurodegenerative disorder, affecting 1–2% of the popu-
lation over the age of 65 [1]. It is a chronic movement
disorder caused by relentless degeneration of specific
neuronal populations in the brain, most notably the
dopamine-producing neurons of the substantia nigra
pars compacta region of the basal ganglia, which helps
control voluntary movement. Patients generally suffer
from the cardinal symptoms of slowness of movement,
tremors while at rest, rigidity, and poor balance, and
often also show autonomic, cognitive, and psychiatric
disturbances. Parkinson’s disease is progressive and may
last 10–20 (or more) years after diagnosis. It is typically
partially treatable (mainly with dopamine-replacement
therapy) for a few years after diagnosis, but this is
generally followed by years of decline during which there
is no effective therapy, eventually leading to premature
death. Parkinson’s disease is usually a sporadic disorder
with onset in later life and the causes of this disease are
incompletely understood. For most of the twentieth
century, genetic predisposition was thought to play a
negligible role in the disease, but in the past 15 years the
identification of distinct genetic loci responsible for
(both the dominant and recessive) inherited forms of
Parkinson’s disease has provided us with numerous clues
to understanding its molecular causes. To date, about 16
Parkinson’s disease-related genetic loci (the PARK loci)
and 11 genes associated with these PARK loci have been
described (see Table 1). Among these genes, 5 have been
studied extensively: a-synuclein (also known as SNCA),
parkin (PARK2), PINK1 (PARK6), DJ-1 (PARK7), and
LRRK2 (PARK8) [2]. Consequently, these will be the
main focus of this review. Recent genome-wide associa-
tion studies (GWAS) have found that having particular
variants of these genes greatly increases the chance of
developing Parkinson’s disease [3,4], suggesting perhaps
that in the cases where the functions are known, the
products of these genes are often proteins involved in the
way brain cells cope with oxidative stress, mitochondrial
dysfunction, and removal of misfolded proteins. A com-
monly held view is that Parkinson’s disease may result
from environmental factors (such as toxins) damaging
dopamine-producing neurons of the substantia nigra in
an accumulative way in individuals who have defects in
pathways dealing with oxidative stress, mitochondrial
dysfunction, and either the ubiquitin proteasome system
or the autophagy-lysosome pathway, which remove mis-
folded proteins (Figure 1). However, some of the im-
plicated proteins have functions that do not necessarily
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plicated.Here,weprovideabriefoverviewofhowgenetic
research and the ensuing molecular insights have led
to substantial advances in our understanding of disease
pathogenesis and in experimental approaches to study
the disorder.
Genetic breakthroughs
The first big breakthrough came in studying the inherited
autosomal-dominant form of Parkinson’s disease, when
mutations of the a-synuclein gene locus were reported in
several families with a history of Parkinson’s disease. Both
[9,10] in the a-synuclein gene cause Parkinson’sd i s e a s e .
Those with a family history of triplications tend to be
younger at disease onset compared to those with duplica-
tions, and the fact that even one copy of the faulty gene
is sufficient to cause the disease suggests that the increa-
sed levels of a-synuclein are in some way toxic [8,11].
Although our knowledge about the normal function of
a-synucleinislimited(weknowthatitmodulatessynaptic
plasticity and regulates neurotransmitter release), recent
studies elucidating the structural properties of this protein
have shed considerable light on its pathogenic involve-
ment in Parkinson’s disease. Both pathogenic mutations
and elevated concentrations will give a-synuclein a
propensity to develop a b-sheet structure which readily
polymerizes into oligomers and higher order aggregates
such as fibrils [12]. a-synuclein aggregation was worsened
by various types of post-translational modifications such
as Ser-129 phosphorylation, calpain-mediated cleavage,
O-glycosylation,tyrosine nitration,methionineoxidation,
and C-terminal truncation [2], although the mechani-
sms are not clear. Insoluble a-synuclein fibrils are a key
component of Lewy bodies (cytoplasmic bodies contain-
ing aggregated proteins), which are the pathogenic hall-
mark of Parkinson’s disease. There is some controversy
as to whether Lewy bodies are a cause or a consequence
of Parkinson’s disease, with some evidence suggesting
that they play a protective role by sequestering toxic
a-synuclein oligomers [13]. However, emerging evidence
from in-vitro studies [14] and animal models [15-18]
suggests that both the oligomer and fibrillar forms of
a-synuclein aggregates are toxic to neurons. However, the
precise roles of a-synuclein aggregation in mediating cell
death in Parkinson’s disease remain elusive, although
there is no shortage of hypotheses. One suggestion is that
a-synuclein oligomers may alter plasma membrane stabi-
lity or permeability by forming membrane pores that
increase intracellular Ca
2+ to toxic levels [20] (Figure 1).
Another suggestion is that because a-synuclein is found at
mitochondrialmembranesofdopaminergicneurons[21],
its overexpression may induce mitochondrial dysfunction
(by inhibiting complex I), and since mitochondria are a
major source of reactive oxygen species, this would result
inincreasedoxidativestress,leadingtoneurodegeneration
[22,23] (Figure 1). Yet another potential mechanism of
a-synuclein toxicity is suggested by the observation that
increased or mutant a-synuclein expression in synaptic
vesicles interferes with synaptic transmission by causing
the accumulation of docked vesicles at the presynaptic
membrane [24], reducing the recycling vesicle pool [25]
and thereby increasing cytosolic dopamine to toxic levels
[26] (Figure 1). Finally, there is the suggestion that as
mutant species of a-synuclein are poor substrates for
proteasomal degradation, they inhibit proteolysis [27],
block lysosomal function [28] (Figure 1) and chaperone-
mediated autophagy [29], and disrupt endoplasmic
reticulum-Golgi trafficking [30,31], causing toxicity.
Table 1: Gene loci identified for Parkinson’s disease and their probable functions
Locus Gene Chromosome Inheritance Probable function
PARK1 & PARK4 a-synuclein 4q21 Dominant Presynaptic protein, Lewy body, lipid and vesicle dynamics
PARK2 parkin 6q25.2-27 Recessive Ubiquitin E3 ligase, mitophagy
PARK3 Unknown 2p13 Dominant Unknown
PARK5 UCHL1 4p14 Dominant Ubiquitin C-terminal hydrolase
PARK6 PINK1 1p35-36 Recessive Mitochondrial kinase
PARK7 DJ-1 1p36 Recessive Oxidative stress
PARK8 LRRK2 12p11.2 Dominant Kinase signaling, cytoskeletal dynamics, protein translation
PARK9 ATP13A2 1p36 Recessive Unknown
PARK10 Unknown 1p32 Dominant Unknown
PARK11 GIGYF2 2p37 Dominant IGF-1 signaling
PARK12 Unknown Xq21-q25 X-linked Unknown
PARK13 Omi/HtrA2 2p13 Unknown Mitochondrial serine protease
PARK14 PLA2G6 22q13 Recessive Phospholipase enzyme
PARK15 FBXO7 22q11 Recessive Ubiquitin E3 ligase
PARK16 Unknown 1q32 Unknown Unknown
ATP13A2, ATPase type 13A2; FBXO7, F-box protein 7; GIGYF2, GRB10 interacting GYF protein 2; HtrA2, HtrA serine peptidase 2 (also known as Omi);
IGF-1, insulin-like growth factor 1; LRRK2, leucine-rich repeat kinase 2; PINK1, PTEN-induced putative kinase 1; PLA2G6, phospholipase A2, group VI
(cytosolic, calcium-independent); UCHL1, ubiquitin carboxyl-terminal esterase L1. Adapted from Hum Mol Genet [68], © 2007.
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andmultiplica-
tions[5-7],inadditiontotriplications[8]andduplications
point mutations (three point mutations)Figure 1. Underlying mechanism of dopaminergic neurodegeneration in Parkinson’s disease
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a-synuclein aggregates exert toxic effects on several
important cellular functions necessary for survival of
dopaminergic neurons.
The second gene mutation identified as causing the
autosomal-dominant form of Parkinson’s disease is that
of LRRK2. LRRK2 mutations cause early-onset Parkinson’s
diseaseinfamiliesfromdiverseethnicbackgrounds,witha
clinical profile identical to sporadic late-onset Parkinson’s
disease. Leucine-rich repeat kinase 2 (LRRK2) is a large
multidomain protein [32], but mutations associated with
Parkinson’sdiseaseareconcentratedinthecentralcatalytic
regions of the GTPase and kinase domains, and most of
them result in increased kinase activity in vitro [32].
Increasedkinaseactivityisknowntopromotecelldeathin
Parkinson’s disease, but the mechanisms are not yet
known. LRRK2 undergoes autophosphorylation and also
phosphorylates a number of protein substrates, so it is
significant that the toxicity of disease-causing mutant
forms of LRRK2 is related totheir enhancedkinase activity
and GTP binding [32-34]. Unsurprisingly, a great deal of
efforthasbeenfocusedonidentifyingthenormalfunction
of LRRK2, including studying its phosphosubstrates,
binding partners, and regulators of its kinase and GTPase
activities, in order to determine how it causes disease.
LRRK2 is thought to play a role in neuronal outgrowth
[35,36], protein translation by phosphorylation of the
translation inhibitor eukaryotic initiation factor 4E
(eIF4E) [37,38], and in cytoskeletal dynamics via phos-
phorylation of moesin, which anchors the cytoskeleton to
the plasma membrane [39]. Mice that harbor LRRK2
mutations develop the cardinal abnormalities of Parkin-
son’s disease in the nigrostriatal system (one of the major
dopaminergic pathways conveying impulses from the
substantia nigra), such as stimulated dopamine neuro-
transmission or behavioral deficits [40]; others show
progressive age-dependent motor deficits that can lead to
immobility but are responsive to the dopaminergic drugs
L-DOPAandapomorphine,anddevelopaxonalspheroids
in striatal and cortical projections composed of phos-
phorylated tau despite an absence of nigrostriatal dopa-
minergic neurodegeneration [41]. Strikingly, there is an
additive effect of expressing mutant forms of LRRK2 and
a-synucleininmice,whereasdeficiencyofLRRK2limitsthe
toxic effects of mutant a-synuclein [42], suggesting that
the two proteins interact. Until recently, it was unclear
whether the neurological features in mice with mutant
LRRK2 result from altered kinase activity. Recent studies
elegantly demonstrated that viral-mediated overexpres-
sion of G2019S mutant LRRK2 in nigrostriatal dopami-
nergic neurons (those located in the substantia nigra
pars compacta and striatum) resulted in marked neuro-
toxicity caused by LRRK2 kinase activity. By contrast,
overexpression of normal or a “kinase-dead”
version of the enzyme did not have this adverse
effect [43]. What’s more, the mutant-LRRK2-mediated
nigrostriatal dopaminergic neurotoxicity was blocked
indirubin-3
0-monoxime [43]. This is encouraging as it
suggests that LRRK2 kinase inhibitors could become a
new treatment for Parkinson’sd i s e a s e .
There have also been advances in understanding from
studying the recessive form of the disease. There is
compelling evidence suggesting that mutations causing a
loss of function in three genes, parkin, PINK1, and DJ-1,
underlie the autosomal-recessive Parkinson’sd i s e a s e
(and also a few cases of sporadic Parkinson’s disease)
[44]. Recent studies have demonstrated that products of
all three genes preserve mitochondrial function and
protect against reactive oxygen species. Patients homo-
zygous for loss-of-function parkin mutations or having
compound heterozygous parkin mutations account for
about 50% of all familial early-onset cases of Parkinson’s
disease, with point mutations being the most frequent
genetic lesion and deletions, duplications, and exonic
rearrangements also contributing to disease [45]. Muta-
tions in PINK1, the second most common autosomal-
recessive mutation (following parkin)c o n t r i b u t et o
between 1% and 7% of early-onset Parkinson’s disease
[46], whereas mutations in DJ-1 are a rare cause of
Parkinson’s disease [47]. There has inevitably been much
study of what the protein products of these genes do.
Parkin tags protein lysine residues with ubiquitin, either
targeting them for destruction via the 26S proteasome
(by adding polyubiquitin chains via lysine K48) or
influencing other signaling pathways such as DNA
repair, endocytosis, transcriptional regulation, and pro-
tein trafficking (by ubiquitination via lysine K48 or K63)
[48]. Disease-causing mutations in parkin lead to a loss of
this E3 ubiquitin ligase activity [48], but although
numerous substrates for parkin have been identified to
date, no consensus has emerged on which of these may
(if not ubiquitinated) lead to neurodegeneration in
Parkinson’s disease (Figure 1).
Several PINK1 mutations are also thought to lead to a loss
offunction[49].PTEN-inducedputative kinase1(PINK1)
is found in the mitochondrial intermembrane space and
membranes of the mitochondria [50], with its serine/
threonine kinase domain facing the cytosol [51], suggest-
ing that its substrates may reside here. Several studies
pointtowardsbothparkinandPINK1havingaprominent
role in preserving mitochondrial function (Figure 1). This
can be seen vividly in parkin or PINK1-mutant/deficient
flies, which exhibit abnormal mitochondria together
with enhanced sensitivity to oxidative stress, apoptotic
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by selective LRRK2 kinase inhibitors GW5074 and
LRRK2muscle degeneration, and significant loss of a subset of
dopaminergicneurons[52-54].Furthermore,micelacking
parkin and PINK1 exhibit nigrostriatal deficits (without
degeneration) and mitochondrial dysfunction (indicated
by reduced activity of multiple respiratory chain com-
plexes) [55,56]. Interestingly, increased expression of
parkin improved dysfunctions in flies lacking PINK1,b u t
increased expression of PINK1 h a dn oe f f e c to nd y s f u n c -
tions inflies lackingparkin[54,57]. This neatly puts parkin
and PINK1 in a common pathway, with PINK1 function-
ing upstream from parkin. This is also consistent with
recent studies where PINK1 was shown to act upstream of
parkin to regulate degradation of damaged mitochondria
by a process known as mitophagy [58,59]. Together these
data provide compelling evidence by which both parkin
and PINK1 play a crucial role in mitochondrial quality
control for Parkinson’s disease. These further reinforce the
similarities between sporadic and familial forms of the
disease, which both implicate mitochondrial dysfunction
as a common pathogenic mechanism.
Parkinson’s disease-associated mutations in the third
gene, DJ-1, produce an inactive molecule that can’tf o r m
a dimer, or lead to no expression at all [60,61]. DJ-1 is a
molecular chaperone with a variety of functions and is
found in the cytosol, the mitochondrial matrix, and
mitochondrial intermembrane space [62]. In cellular
models, it regulates oxidation-reduction-dependent sig-
nalingpathwaysandactsasaregulatorofantioxidantgene
expression [63], and gene deletion studies show that it
counters oxidative stress in mitochondria [64]. Recent
studies indicate that DJ-1 deficiency is associated with
apoptosis,perturbed mitochondrialdynamics,andautop-
hagic dysregulation [65-67], linking it with functions
mediated by both parkin and PINK1 (Figure 1). Future
studies focused on the interplay between PINK1, parkin,
andDJ-1willhopefullygreatlyadvancetheunderstanding
ofhow mutations in these genes cause Parkinson’sd i s e a s e
and what the common underlying mechanisms are.
Future directions
The identification and characterization of familial
Parkinson’s disease-linked genes has sparked an extre-
mely fruitful line of research, delineating molecular
pathways that are involved in the pathogenesis of
Parkinson’s disease. Although the genetic mutations in
known genes account for only a limited fraction of the
heritable forms of Parkinson’s disease, the use of high-
throughput exome and genome sequencing in the future
are likely to identify additional rare variants that will
further expand our knowledge of pathogenic disease
mechanisms. So far, the proteins that have been linked to
Parkinson’s disease by genetic studies have roles in lipid
and vesicle dynamics (a-synuclein), the ubiquitin-
proteasome system (parkin), cytoskeletal dynamics,
protein translation, abnormal kinase function (LRRK2),
oxidative stress, and mitochondrial dysfunction (DJ-1,
PINK1, parkin). Evidently, these disparate functions
must overlap as they lead to the dysfunction and death
of dopaminergic neurons characteristic of Parkinson’s
disease. As discussed above these molecular pathways
and functions are not only relevant for the rare familial
variants of Parkinson’s disease, but also to the more
common sporadic version of the disease.
However, while we have made great strides in under-
standing, the relationships between these functions are
not direct and the connections between them are not
immediately apparent. Therefore, the major focus in the
future should beto identifycommon underlying mechan-
isms by which familial Parkinson’s disease-linked genes
affect dopaminergic neuronal survival, to hopefully
provide the basis for new and tractable targets for new
drugs to prevent and treat Parkinson’sd i s e a s e .
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